Catalyst Biosciences Participating in a Fireside Chat with LifeSci Capital
September 15 2021 - 7:00AM
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the
members of its management team will participate in a fireside chat
hosted by LifeSci Capital on Wednesday, September 15, 2021 at 1:00
pm Eastern Time.
Catalyst Biosciences’ management team will discuss the progress
made in the Company’s complement portfolio including CB 2782-PEG
(C3 degrader), CB 4332 (enhanced CFI), and selective degraders of
C4b/C3b and C3a/C5a.
To register for the call, please e-mail
rfromberg@lifescicapital.com. The replay will also be available on
the Events and Presentations section on the Company’s
website for approximately 90 days.
About Catalyst Biosciences, the Protease Medicines
companyCatalyst is a research and clinical development
biopharmaceutical company focused on addressing unmet medical needs
in rare disorders of the complement and coagulation systems. Our
protease engineering platform has generated two late-stage clinical
programs, including MarzAA, a subcutaneously (SQ) administered
next-generation engineered coagulation Factor VIIa (FVIIa) for the
treatment of episodic bleeding in subjects with rare bleeding
disorders. Our complement pipeline includes a preclinical
C3-degrader program licensed to Biogen for dry age-related macular
degeneration, an improved complement factor I protease for SQ
replacement therapy in patients with CFI deficiency and proteases
from our ProTUNE™ C3b-C4b degrader and ImmunoTUNE™ C3a-C5a degrader
platforms designed to target specific disorders of the complement
or inflammatory pathways as well as other complement programs in
development.
Forward-Looking StatementsThis press release
contains forward-looking statements that involve substantial risks
and uncertainties. Forward-looking statements include, without
limitation, statements about the product candidates
of Catalyst Biosciences, Inc. (the “Company”) and the
benefits of its protease engineering platform; plans to complete
the ConFIrm and ConFIdence studies; plans to submit an IND and
initiate a global clinical trial for CB 4332 in CFI deficiency in
2022; the potential markets for and advantages of the Company's
complement product candidates, including CB 2782-PEG, CB 4332 and
complement degraders; and plans for the Company's collaboration
with Biogen.
Actual results or events could differ materially from the plans,
intentions, expectations and projections disclosed in the
forward-looking statements. Various important factors could cause
actual results or events to differ materially, including, but not
limited to, the risk that trials and studies may be delayed or
halted as a result of COVID-19, competitive products and other
factors, that trials may not have satisfactory outcomes, the risk
that the ConFIrm and ConFIdence trials will not validate the
potential market for CB 4332; the risks that CB4332 and the
Company’s complement degraders have not yet started human clinical
trials, the risk Catalyst may elect to terminate or postpone
ongoing development programs, including development of MarzAA or
any of the Company’s complement assets; the risk that the Company
will need to raise additional capital, which may not be available
on favorable terms if at all; the risk that Biogen may terminate
the Company's agreement, and other risks described in the "Risk
Factors" section of the Company's Annual Report on Form 10-K filed
with the Securities and Exchange Commission (the “SEC”)
on March 4, 2021, the Quarterly Report on Form 10-Q filed with
the SEC on August 5, 2021 and in other filings filed from time to
time with the SEC. The Company does not assume any obligation
to update any forward-looking statements, except as required by
law.
Contact:
Ana KaporCatalyst Biosciences, Inc.investors@catbio.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Apr 2024 to May 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From May 2023 to May 2024